Incyte Corporation  

(Public, NASDAQ:INCY)   Watch this stock  
Find more results for INCY
71.00
-1.03 (-1.43%)
Feb 5 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 68.00 - 71.56
52 week 64.51 - 133.62
Open 70.68
Vol / Avg. 4.47M/2.47M
Mkt cap 13.02B
P/E     -
Div/yield     -
EPS -0.49
Shares 186.00M
Beta 0.79
Inst. own 97%
Feb 11, 2016
Q4 2015 Incyte Corp Earnings Call - 10:00AM EST - Add to calendar
Feb 11, 2016
Q4 2015 Incyte Corp Earnings Release - 7:00AM EST - Add to calendar
Jan 11, 2016
Incyte Corp at JPMorgan Healthcare Conference - Webcast
Nov 11, 2015
Eli Lilly and Co and Incyte Corp Webcast to Discuss Baricitinib Phase 3 Data - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -21.10% -9.48%
Operating margin -0.05% -0.94%
EBITD margin - 7.16%
Return on average assets -17.05% -6.64%
Return on average equity -220.64% -
Employees 588 -
CDP Score - -

Address

1801 Augustine Cut off
WILMINGTON, DE 19803-4404
United States - Map
+1-302-4986700 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Incyte Corporation is a biopharmaceutical company focused on the discovery development and commercialization of small molecule drugs to treat serious unmet medical needs. The Company's compound JAKAFI (ruxolitinib) also known as INCB18424 and INC424 is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or highrisk myelofibrosis (MF) including primary MF postpolycythemia vera MF and postessential thrombocythemia MF. The Company has a second oral JAK1 and JAK2 inhibitor LY3009104 (INCB28050) , which is subject to a collaboration agreement with Eli Lilly and Company in , which Lilly received development and commercialization rights f

Officers and directors

Herve Hoppenot President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Julian C. Baker Independent Vice Chairman of the Board
Age: 49
Bio & Compensation  - Reuters
David W. Gryska Chief Financial Officer, Executive Vice President
Age: 59
Bio & Compensation  - Reuters
Reid M. Huber Executive Vice President, Chief Scientific Officer
Age: 43
Bio & Compensation  - Reuters
Eric H. Siegel Executive Vice President, General Counsel
Age: 50
Bio & Compensation  - Reuters
Paula J. Swain Executive Vice President - Human Resources
Age: 57
Bio & Compensation  - Reuters
Barry P. Flannelly Executive Vice President - Business Development and Strategic Planning
Age: 57
Bio & Compensation  - Reuters
Richard S. Levy M.D. Executive Vice President, Chief Drug Development and Medical Officer
Age: 57
Bio & Compensation  - Reuters
Wenqing Yao Ph.D. Executive Vice President - Discovery Medicinal and Process Chemistry
Age: 52
Bio & Compensation  - Reuters
Steven H. Stein M.D. Senior Vice President and Chief Medical Officer
Bio & Compensation  - Reuters